180 related articles for article (PubMed ID: 4053027)
1. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.
Leopold WR; Nelson JM; Plowman J; Jackson RC
Cancer Res; 1985 Nov; 45(11 Pt 1):5532-9. PubMed ID: 4053027
[TBL] [Abstract][Full Text] [Related]
2. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
Krapcho AP; Menta E; Oliva A; Di Domenico R; Fiocchi L; Maresch ME; Gallagher CE; Hacker MP; Beggiolin G; Giuliani FC; Pezzoni G; Spinelli S
J Med Chem; 1998 Dec; 41(27):5429-44. PubMed ID: 9876113
[TBL] [Abstract][Full Text] [Related]
4. Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles.
Showalter HD; Fry DW; Leopold WR; Lown JW; Plambeck JA; Reszka K
Anticancer Drug Des; 1986 Apr; 1(2):73-85. PubMed ID: 2453196
[TBL] [Abstract][Full Text] [Related]
5. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
Wallace RE; Murdock KC; Angier RB; Durr FE
Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of cis-dichlorodiammineplatinum(II).
Wolpert-DeFilippes MK
Cancer Treat Rep; 1979; 63(9-10):1453-8. PubMed ID: 498146
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor activity of bizelesin in mice.
Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
[TBL] [Abstract][Full Text] [Related]
8. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
[TBL] [Abstract][Full Text] [Related]
9. Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.
Showalter HD; Johnson JL; Hoftiezer JM; Turner WR; Werbel LM; Leopold WR; Shillis JL; Jackson RC; Elslager EF
J Med Chem; 1987 Jan; 30(1):121-31. PubMed ID: 3806589
[TBL] [Abstract][Full Text] [Related]
10. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
Staquet MJ; Byar DP; Green SB; Rozencweig M
Cancer Treat Rep; 1983 Sep; 67(9):753-65. PubMed ID: 6883351
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues.
Leopold WR; Shillis JL; Mertus AE; Nelson JM; Roberts BJ; Jackson RC
Cancer Res; 1984 May; 44(5):1928-32. PubMed ID: 6546897
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.
Plowman J; Harrison SD; Dykes DJ; Paull KD; Narayanan VL; Tobol HK; Martin J; Griswold DP
Cancer Res; 1989 Apr; 49(8):1909-15. PubMed ID: 2702634
[TBL] [Abstract][Full Text] [Related]
13. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
Schabel FM; Trader MW; Laster WR; Corbett TH; Griswold DP
Cancer Treat Rep; 1979; 63(9-10):1459-73. PubMed ID: 291480
[TBL] [Abstract][Full Text] [Related]
14. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
Finch RA; Shyam K; Penketh PG; Sartorelli AC
Cancer Res; 2001 Apr; 61(7):3033-8. PubMed ID: 11306484
[TBL] [Abstract][Full Text] [Related]
15. 8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
Stefańska B; Dzieduszycka M; Bontemps-Gracz MM; Borowski E; Martelli S; Supino R; Pratesi G; De Cesare M; Zunino F; Kuśnierczyk H; Radzikowski C
J Med Chem; 1999 Sep; 42(18):3494-501. PubMed ID: 10479282
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 2-chloroethyl (methylsulfonyl)methanesulfonate (clomesone, NSC 33847) against selected tumor systems in mice.
Dykes DJ; Waud WR; Harrison SD; Laster WR; Griswold DP; Shealy YF; Montgomery JA
Cancer Res; 1989 Mar; 49(5):1182-6. PubMed ID: 2537144
[TBL] [Abstract][Full Text] [Related]
17. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
Hickman JA; Stevens MF; Gibson NW; Langdon SP; Fizames C; Lavelle F; Atassi G; Lunt E; Tilson RM
Cancer Res; 1985 Jul; 45(7):3008-13. PubMed ID: 4005840
[TBL] [Abstract][Full Text] [Related]
18. Anthrapyrazoles: true successors to the anthracyclines?
Judson IR
Anticancer Drugs; 1991 Jun; 2(3):223-31. PubMed ID: 1802016
[TBL] [Abstract][Full Text] [Related]
19. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
20. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice.
Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H
Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
